ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00539435
Recruitment Status : Withdrawn (Administrative)
First Posted : October 4, 2007
Last Update Posted : August 10, 2016
Sponsor:
Collaborator:
Advanced Diabetes Treatment Centers
Information provided by (Responsible Party):
Florida Atlantic University

Brief Summary:
The purpose of this study is to determine if restoring normal metabolic function in patients with either type I or type II diabetes can improve the impact of the consequences of diabetic complications on heart disease in diabetic patients. Patients are treated once a week with pulsatile intravenous insulin therapy mimicking normal insulin secretion. A diabetic cardiac disease quality of life questionnaire is completed prior to the start of the treatment and monthly thereafter with detailed analysis performed to measure progress and outcomes. A carotid ultrasound and echocardiogram are performed at baseline and every six months to monitor progress.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, With Complications Procedure: Intravenous Insulin on cardiac disease in diabetic pts Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes
Study Start Date : September 2007
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
Procedure: Intravenous Insulin on cardiac disease in diabetic pts
Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
Other Name: Humulin R, Novolog



Primary Outcome Measures :
  1. Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress. [ Time Frame: Testing is performed at baseline and every six months thereafter. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The researchers will include up to 400 pts between male and female between the ages of 21 and 85 diagnosed with diabetes mellitus and cardiac disease
  • Self reporting or diagnosed with significant complications resulting from diabetes
  • Taking oral agents and/or insulin for diabetic control
  • Under an Endocrinologist supervision for their diabetes management, Endocrinologist must assess and approve pt for participation in this study
  • Ability to swallow without difficulty
  • Ability to perform Respiratory Quotient requirements by breathing into a mask for 3 minutes at a time

Exclusion Criteria:

  • Lack of Intravenous access
  • Pregnancy
  • Alcohol abuse, drug addiction or the use of illegal drugs
  • Active liver disease
  • Active chemotherapy
  • Positive HIV
  • Inability to breathe into a respiratory quotient machine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00539435


Locations
United States, Florida
Betty Tuller PhD
Boca Raton, Florida, United States, 33431
Sponsors and Collaborators
Florida Atlantic University
Advanced Diabetes Treatment Centers
Investigators
Principal Investigator: Betty Tuller, PhD Florida Atlantic University

Responsible Party: Florida Atlantic University
ClinicalTrials.gov Identifier: NCT00539435     History of Changes
Other Study ID Numbers: H09-124
First Posted: October 4, 2007    Key Record Dates
Last Update Posted: August 10, 2016
Last Verified: August 2016

Keywords provided by Florida Atlantic University:
Diabetes Mellitus
Pulsatile Intravenous Insulin Therapy
Diabetic Cardiac Quality of Life
Cardiac Disease

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases
Insulin, Globin Zinc
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs